Alban Carlos's most recent trade in SpringWorks Therapeutics Inc was a trade of 30,160 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on July 1, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| SpringWorks Therapeutics Inc | Carlos Alban | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 Jul 2025 | 30,160 | 0 | - | - | Stock Option (Right to Buy) | |
| SpringWorks Therapeutics Inc | Alban Carlos | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 Jul 2025 | 28,861 | 0 (0%) | 0% | - | Common Stock | |
| SpringWorks Therapeutics Inc | Carlos Alban | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 Jul 2025 | 13,774 | 0 | - | - | Stock Option (Right to Buy) | |
| SpringWorks Therapeutics Inc | Alban Carlos | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 Jul 2025 | 12,216 | 0 | - | - | Stock Option (Right to Buy) | |
| SpringWorks Therapeutics Inc | Carlos Alban | Director | 14 May 2025 | 10,060 | 28,861 (0%) | 0% | 0 | Common Stock | ||
| Solventum | Carlos Alban | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 May 2025 | 3,564 | 0 | - | - | Restricted Stock Units | |
| Solventum | Carlos Alban | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 May 2025 | 3,564 | 3,564 | - | 0 | Common Stock | |
| Solventum | Carlos Alban | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Apr 2025 | 3,403 | 3,403 | - | - | Restricted Stock Units | |
| SpringWorks Therapeutics Inc | Carlos Alban | Director | 16 May 2024 | 12,216 | 12,216 | - | - | Stock Option (Right to Buy) | ||
| SpringWorks Therapeutics Inc | Carlos Alban | Director | 16 May 2024 | 4,095 | 18,801 (0%) | 0% | 0 | Common Stock | ||
| Solventum | Carlos Alban | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 May 2024 | 3,564 | 3,564 | - | - | Restricted Stock Units | |
| Solventum | Carlos Alban | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 May 2024 | 1,980 | 5,544 | - | - | Restricted Stock Units | |
| SpringWorks Therapeutics Inc | Carlos Alban | Director | 24 May 2023 | 13,774 | 13,774 | - | - | Stock Option (Right to Buy) | ||
| SpringWorks Therapeutics Inc | Carlos Alban | Director | 24 May 2023 | 4,648 | 14,706 (0%) | 0% | 0 | Common Stock | ||
| SpringWorks Therapeutics Inc | Carlos Alban | Director | 14 Jul 2022 | 30,160 | 30,160 | - | - | Stock Option (Right to Buy) | ||
| SpringWorks Therapeutics Inc | Carlos Alban | Director | 14 Jul 2022 | 10,058 | 10,058 (0%) | 0% | 0 | Common Stock |